Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

IntelliCell BioSciences Signs Letter of Intent With Prestigious Southeastern Medical Center for Cellular Therapy Lab Suite


NEW YORK, NY--(Marketwired - Oct 1, 2015) - IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company pioneering a new proprietary medical process that results in acquiring Stromal Vascular Fraction Cells (SVFC), announced today the Company has signed a Letter of Intent with a prestigious Medical Center (the Center) in the Southeastern U.S. for the purchase of an Intellicell U.S. Food and Drug Administration (FDA) registered Cellular Therapy Lab Suite.

Dr. Steven Victor, CEO of IntelliCell BioSciences, stated "The Letter of Intent outlines a basic understanding between Intellicell and the Center for the purchase of an Intellicell FDA registered Cellular Therapy Lab Suite. Due to confidentiality, the Center has not been specifically named. However, this Center is our first off site cGTP lab suite and we are excited to work with the physician group and their professional staff. We will still be responsible for the Quality Assurance of the lab and similar to our New York lab, we intend to register this facility with the FDA and we are confident that we will be able to help with the FDA inspection."

About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous Stromal Vascular Fraction Cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.

Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.


Intellicell Biosciences, Inc.
Office: 212 249 3050

Public Relations
Sean Leous
Managing Director
Phone: 1 646 863 8998